Provided are the use of a mutant Ovis spp. infectious pustular dermatitis virus (ORFV) and a pharmaceutical composition thereof in the treatment of cancer.

The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.

The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.

The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased munogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus vector and/or said cell, and a new use of said modified Parapoxvirus.

Provided are the use of a mutant Ovis spp. infectious pustular dermatitis virus (ORFV) and a pharmaceutical composition thereof in the treatment of cancer.